Sanofi’s LAVA Therapeutics LVTX Stock Holding History

Sanofi’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,919,455	Closed	-$2.99M	–	9
2025 Q3	$2.99M	Hold	1,919,455	–	–	1.15%	7
2025 Q2	$2.53M	Hold	1,919,455	–	–	1.44%	6
2025 Q1	$2.44M	Hold	1,919,455	–	–	1.47%	6
2024 Q4	$1.83M	Buy	+1,919,455	New	+$3.01M	1.05%	7

Sanofi's LVTX Position: Q4 2025 in Review

Sanofi sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 1,919,455 shares — an estimated $2.99M sold.

Sanofi first reported a position in LVTX in Q4 2024 and held it in 4 quarters. The position peaked at $2.99M in Q3 2025. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

Sanofi reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
Sanofi sold 1,919,455 LAVA Therapeutics shares in Q4 2025, an estimated $2.99M.
Sanofi first reported a position in LAVA Therapeutics in Q4 2024 and held it in 4 quarters.
Sanofi's LAVA Therapeutics position peaked at $2.99M in Q3 2025.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on Sanofi's 13F filing for Q4 2025, filed 11 Feb 2026.